Dyadic International Inc (DYAI): Cash & Equivalents
$4.62M
As of 2025-12-31
$1.43M
As of 2026-06-30
-7.3%
3-year compound annual growth
-25.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.62M | -29.0% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $6.51M | -0.1% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $6.52M | +12.4% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $5.79M | -63.2% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $15.75M | -23.7% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $20.64M | +327.8% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $4.82M | +102.1% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $2.39M | -58.8% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $5.79M | n/a | 2019-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Dyadic International Inc (DYAI) | 2025-12-31 | $4.62M | -29.0% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $89.25M | +158.2% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $347.56M | +16.5% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $32.49M | -87.4% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $63.03M | -65.5% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $194.17M | +498.2% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
Compare DYAI, SRZN, CRSP, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗